GeneproDX is bringing cutting-edge diagnostics to patients by providing the first and only globally available diagnostic test for patients with indeterminate thyroid nodules (ThyroidPrint). We will offer a seamless sample-to-insight testing in under 48 hours by using a globally Idylla available diagnostic platform, providing access to hundreds of thousands of underserved patients around the world.

GeneproDX is transforming traditional medicine — bridging Health Tech and AI and providing patients with fast, reliable, and accurate diagnostics. GeneproDX’s patented product, ThyroidPrint, is widely used by doctors in Latin America with plans for expansion to the U.S. and Europe in 2022. ThyroidPrint provides highly-accurate diagnosis, resulting in fewer unnecessary surgeries — saving patients from life-altering surgical outcomes.